Vironexis

Vironexis is committed to transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV gene therapy platform enables the creation of off-the-shelf, single-dose gene therapies designed to address the key challenges and limitations faced by current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes over a dozen candidate products for the treatment of hematologic malignancies, solid tumor metastasis prevention, and cancer vaccines. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is expected to enter clinical trials in the fourth quarter of 2024.